The effect of silymarin on Alzheimer’s diseases

The effect of silymarin on inflammatory factors TNF-a and IL-1ß and it’s probable relationship with cognitive function of Alzheimer’s patients.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131219015870N3

Enrollment

Registered

2018-06-10

Start date

2018-02-24

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease. Alzheimer's disease

Interventions

Intervention group: daily 3 tablets of 140 mg silymarin for 3 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who diagnosed with brain imaging and biochemical tests, Alzheimer's by a neurologist

Exclusion criteria

Exclusion criteria: epilepsy heart failure CKD hypothyroidism vitamon b 12 deficiency psychiatric desease stroke brain tumor hydrocephaly encephalitis pragnancy excerbation of symptoms when patiants want to start silymarin

Design outcomes

Primary

Measure	Time frame
Score of cognitive function in Mini Mental State Examination. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: Mini Mental State Examination.;Serum levels of TNF-a inflammatory factor. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: ELISA.;Serum levels of IL-1ß inflammatory factor. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: ELISA.	—

Measure

Time frame

Score of cognitive function in Mini Mental State Examination. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: Mini Mental State Examination.;Serum levels of TNF-a inflammatory factor. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: ELISA.;Serum levels of IL-1ß inflammatory factor. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr amir kiani

Kermanshah University of Medical Sciences

akiani@kums.ac.ir+98 83 3427 6493

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026